Study Overview: This study looks at a new treatment, called bb2121, for people with a type of cancer called multiple myeloma (MM). Multiple myeloma affects the blood, and this study is for people whose cancer has come back (relapsed) or didn’t get better with other treatments (refractory). The study will test how well bb2121 works and how safe it is.
Participants: The study is divided into groups called cohorts, each with different conditions and previous treatments. There are about 264 people in total. Participants need to be at least 18 years old and have certain medical conditions related to MM.
Key Points:
- Participants may have to take other medications while waiting for bb2121 to be ready.
- The study is conducted at multiple locations and is open-label, meaning both the doctors and participants know what treatment is being given.
- Participants must not have certain health issues or have used certain treatments recently to join the study.
How understandable was the trial content above?
Hard to understand
Easy to understand